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Objectives: A growing body of literature has highlighted the importance of considering 
patient preferences as part of the medical decision-making process. The purpose of the current 
review was to identify and summarize published research on preferences related to attention-
deficit/hyperactivity disorder (ADHD) and its treatment, while suggesting directions for future 
research.
Methods: A literature search identified 15 articles that included a choice-based assessment of 
preferences related to ADHD.
Results: The 15 studies were grouped into four categories based on preference content: prefer-
ence for a treatment directly experienced by the respondent or the respondent’s child; preference 
for general treatment approaches; preference for a specific treatment attribute or outcome; and 
preference for aspects of ADHD-related treatment. Preference assessment methods ranged 
from global single items to detailed choice-based procedures, with few studies using rigor-
ously developed assessment methods. Respondents included patients with ADHD, clinicians, 
parents, teachers, and survey respondents from the general population. Factors influencing 
preference include treatment characteristics, effectiveness for specific symptoms, side effects, 
and respondent demographics. Minimal research has examined treatment preferences of adults 
with ADHD.
Discussion: Because there is no dominant treatment known to be the first choice for all patients, 
ADHD is a condition for which individual preferences can play an important role when making 
treatment decisions for individual patients. Given the potential role of preferences in clinical 
decision-making, more research is needed to better understand the preferences of patients with 
ADHD and other individuals who are directly affected by the disorder, such as parents and 
teachers.
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Objectives
A growing body of literature has highlighted the importance of considering patient 
preferences as part of the medical decision-making process.1–3 Consequently, studies 
have assessed patient preferences for treatment options across a wide range of medical 
and psychiatric conditions such as cancer,4–6 allergic rhinitis,7 depression,8 migraine,9 
diabetes,10 and osteoporosis.11 Several studies have examined preferences for treat-
ment of attention-deficit/hyperactivity disorder (ADHD), which is characterized by 
symptoms of inattention, hyperactivity, and impulsivity.12 Research on preferences 
for treatment of childhood ADHD raises methodological questions as studies often 
examine preferences of individuals other than the children themselves, such as parents, 
teachers, clinicians, and the general public. In addition, although awareness of adult Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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ADHD is growing,13–16 little is known about preferences of 
adults with ADHD. Thus, the purpose of the current review 
was to identify and summarize published research on prefer-
ences related to ADHD and its treatment, while suggesting 
directions for future research.
Background: patient preference
Despite the range of definitions in the literature, there appears 
to be a consensus that the term ‘patient preference’ refers to 
a patient’s perception of the relative desirability of more than 
one health-related option.17–20 Research has been conducted 
to identify and quantify patient preferences for a wide range 
of treatment options and health states. For example, some 
studies have asked patients to indicate which treatment option 
they preferred after receiving multiple treatments in a clinical 
trial with a crossover design.7,9,21 Research participants have 
also been asked to express preferences among hypothetical 
health states that they have not necessarily experienced.22 
Preferences of individual patients may also be considered in 
clinical settings as part of a shared patient–clinician decision-
making process.17
Patient preference is considered important for several 
reasons. First, there is growing awareness that active patient 
participation in the medical decision-making process may 
have potential treatment benefits.17,18 Patients often want to 
be involved in these decisions,23 and studies have found that 
greater patient involvement in health care decisions may 
be associated with increased treatment adherence, symp-
tom relief, and treatment satisfaction.8,24–27 When making 
treatment decisions with individual patients, the patient’s 
preferences are likely to be consistent with evidence-based 
medicine and generally accepted clinical practices.3 However, 
there are circumstances when individual patient preferences 
diverge from those of health professionals and the general 
public.19 Individual patient preferences may be most impor-
tant when clinical trial results have not yet indicated which 
treatment option tends to be more effective or when similarly 
effective treatment options could have different effects on 
quality of life.17
Patient preference data collected in clinical trials and 
other studies could substantially contribute to large-scale 
health care decision-making. Patient preferences identified 
within studies involving larger samples can provide an 
indication of comparative treatment effectiveness in the 
total sample and among meaningful patient subgroups, 
which may help guide clinicians when deciding how to 
treat individual patients. In addition, preference data may 
shape broader treatment recommendations, as these data 
provide an indication of the patient’s perspective that 
could be used by decision-makers when drafting treatment 
guidelines and health policy.17 Patient preferences are also 
used to quantify the health-related quality of life of health 
states. These resulting estimates called utilities, with val-
ues of 1 corresponding to full health and 0 corresponding 
to death, quantify health outcomes and treatment benefits 
and are used in cost-utility analyses which inform medical 
decision-making.28,29
Patient preferences are assessed with a wide variety of 
methods, ranging from global items to more detailed choice-
based assessment methods. Some studies, including many 
clinical trials, have used straightforward single items asking 
patients which they prefer among two or more treatment 
options. In clinical trials with crossover designs, these single 
items may be used to assess preferences among treatments 
that the patients have recently experienced.30–32 In other 
studies, patients may be asked to express preferences among 
a range of treatments or health-related options that they 
have not personally experienced.33–36 Occasionally, global 
preference questions may be followed by Likert scale items 
assessing the strength of preference for the various options.19 
Studies aiming to quantify preferences in terms of utilities 
often use more complex methodology involving choices 
between hypothetical health state options. These methods, 
such as standard gamble (SG) and time-trade-off procedures, 
have been summarized previously.29,37,38 The current review 
summarizes literature using any of these methods to assess 
preferences associated with ADHD.
Literature review methods
A literature search was conducted using the PubMed database 
with no restrictions on date of publication. An initial search 
for citations mentioning ADHD or any terms related to the 
disorder yielded 13,495 citations. Then, a second search 
identified articles relating to preference, using search terms 
corresponding to preference in a general sense, terms refer-
ring to a specific preference assessment method, and terms 
that could be related to preference such as acceptability and 
decision-making. These search terms included all forms 
(eg, singular and plural, abbreviations, alternative spellings, 
noun, and verb forms) of the following: health state utility, 
utility, discrete choice, standard gamble, time trade-off, 
quality-adjusted life year, conjoint analysis, patient prefer-
ence, preference, prefer, satisfaction, acceptability, decision, 
and choice. The preference search, which yielded 757,804 
citations, was then crossed with the ADHD search resulting 
in 1005 abstracts.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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The 1005 abstracts, and full-text articles when necessary, 
were reviewed to identify articles meeting inclusion/exclu-
sion criteria. For this literature review, ‘preference’ was 
conceptualized based on the definition proposed by Brennan 
and Strombom:18 ‘statements made by individuals regarding 
the relative desirability of a range of health experiences, 
treatment options, or health states’. For a study to be con-
sidered a ‘preference study’, it was required that respondents 
were given a choice among multiple health-related options. 
Questionnaires or interviews assessing perceptions of a single 
treatment without comparison to an alternative option were 
not considered to be preference assessments, even if articles 
used terms that initially appeared to be relevant, such as 
‘prefer’ or ‘choice’. Both informal methods (eg, unvalidated 
single items or interviews) and formal methods (eg, SG, 
time-trade-off, and discrete choice experiments) for assess-
ing preference were included. Preferences of children with 
ADHD, adults with ADHD, parents, teachers, clinicians, 
and the general public were all considered to be relevant for 
the current review.
The following citations were excluded: review articles, 
conference presentations, letters, practice guidelines, case 
studies, and editorials. Cost-effectiveness and cost-utility 
analyses were not included, but these articles were examined 
in order to identify any utility or preference data that may 
have been cited. Articles focusing on conceptually related 
topics such as treatment acceptability, treatment satisfac-
tion, treatment-related attitudes, and decision-making were 
excluded if respondents were not asked to indicate a pref-
erence among multiple health-related options. Although 
multiattribute measures such as the EQ-5D® and Health 
Utilities Index have scoring algorithms that were derived 
via preference-based tasks, studies administering these 
instruments were not included in the current review because 
respondents do not explicitly indicate preferences when 
completing these questionnaires.
Results: ADHD preference studies
Summary of preference studies
A total of 15 articles were identified that included a choice-
based assessment of preference related to ADHD. For the 
current review, these 15 studies are organized into four cat-
egories based on the content of the preference assessment: 
1) five studies assessing preference for a treatment directly 
experienced by the respondent or the respondent’s child with 
ADHD, 2) four studies assessing preference for general treat-
ment approaches, 3) four studies assessing preference for a 
specific treatment attribute or outcome, and 4) two studies 
that did not fit into the three other categories because they 
did not examine preference for a treatment-related aspect 
of ADHD.
Seven studies that were excluded from this review used 
the term ‘preference’ when describing methods or results, but 
did not appear to include a choice-based assessment of pref-
erence among health-related options. Three of these seven 
studies used qualitative interview or focus group methods to 
elicit open-ended responses,39–41 and the remaining four stud-
ies administered rating scales that assessed related constructs 
such as importance and acceptability.42–45 These seven studies 
were excluded from the current review because they were not 
consistent with generally accepted definitions of ‘preference’, 
which involves a choice between two or more options.
Studies assessing preference for  
a specific experienced treatment
Five studies assessed preference for a treatment directly 
experienced by the respondent or the respondent’s child 
(Table 1). Three of the five studies presented results from 
clinical trials of medication treatment for ADHD in chil-
dren and/or adolescents.46–48 Because these studies focus 
on efficacy and safety of medication treatment, the pub-
lished articles do not provide a detailed description of the 
preference assessment methods. The study by Efron et al46 
specified that a single-item assessment was completed by 
parents of children treated for ADHD, while the articles 
by Quintana et al47 and Pelham et al48 do not specify the 
preference assessment method. In the study by Efron et al,46 
the single-item assessment was completed at the end of 
the 4-week crossover trial of methylphenidate (MPH) and 
dexamphetamine (DEX), with findings indicating that more 
parents preferred the 2-week MPH treatment period over 
the 2-week DEX treatment period (46.6% vs 36.8% of par-
ents). In the placebo-controlled, three-way crossover trial by 
Pelham et al,48 children received treatment with immediate-
release (IR) MPH three times daily, MPH once daily, and 
placebo, each for a 7-day period. Results from the unspeci-
fied preference assessment completed by parents at the end 
of the three treatment periods found that 47% of parents 
selected the once daily MPH formulation as the treatment 
of choice for their child versus 31% of parents who selected 
the immediate-release formulation taken three times daily. 
Finally, the study by Quintana et al47 presents results from 
a 6-week clinical trial in which children and adolescents 
switched from psychostimulant treatment to treatment with 
atomoxetine. Although the preference assessment method 
and preference evaluator were not clearly specified in the Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Table 1 Studies assessing preference for treatments directly experienced by the respondents or their children
Citation Preference assessment  
method
Preference content Respondent (N) Key results
efron  
et al46
Single-item assessment of  
preference at end of  
treatment period in a  
crossover trial (no further  
details provided)
Children received treatment with  
MPH and DeX, each for 2 weeks  
in a double-blind, crossover trial.  
After both treatment periods,  
parents were asked to specify  
which treatment they preferred
Parents of children  
(mean age of 8.73  
years) with ADHD  
(N = 125)
46 of 104 parents (36.8%) 
indicated that they preferred 
the DeX treatment period, 
and 58 parents (46.4%) 
indicated that they preferred 
the MPH treatment period
Fredericks  
and Kollins49
Double-blind  
choice procedure
Participants received double-blind  
treatment with either placebo or  
MPH during four study ‘sampling  
sessions’. During eight subsequent  
‘choice sessions’, participants  
chose which treatment they would  
receive: placebo, MPH, or neither
Adults with ADHD  
(N = 10)
MPH was preferred in 50% of 
the choices; placebo 32.5%, 
neither 17.5% (significant 
difference among choices; 
χ2 = 52.5, P , 0.001)
MacDonald  
Fredericks  
and Kollins50
Double-blind  
choice procedure
Participants received double-blind  
treatment with either placebo or  
MPH during six study ‘sampling  
sessions’. During six subsequent  
‘choice sessions’, participants  
chose which treatment they would  
receive: placebo, MPH, or neither
Children/adolescents  
(aged 10–14) with  
ADHD (N = 5)
MPH was preferred in 60% 
of the choices; placebo 20%; 
neither 20% (significant 
difference among choices; 
χ2 = 9.6, P , 0.01)
Pelham  
et al48
Unspecified preference  
assessment completed at  
end of double-blind,  
placebo-controlled,  
clinical trial
Children received treatment with  
placebo, iR MPH (three times daily),  
and a once daily MPH formulation  
in a randomly selected order.  
At the end of the three 7-day  
treatment periods, parents were  
asked to choose which of the  
treatment weeks they preferred  
for their child
Parents of children  
with ADHD (aged  
6–12) (N = 68)
47% of the parents selected 
once daily MPH as the 
treatment of choice, 31% 
selected iR MPH, 15% chose 
their child’s previous MPH 
treatment, and 7% either 
chose placebo or had no 
preference
Quintana  
et al47
Unspecified preference  
assessment completed  
at end of clinical trial
in this 6-week study, children and  
adolescents with incomplete  
response or intolerance to  
stimulant treatment switched to  
atomoxetine after the first week.  
The two treatments were  
compared using an unspecified  
preference assessment method
Children and  
adolescents (aged  
6–17 years) with  
ADHD (N = 58)
65.5% of subjects reported a 
preference for atomoxetine 
treatment over their previous 
psychostimulant
Abbreviations: MPH, methylphenidate; DEX, dexamphetamine; ADHD, attention-deficit/hyperactivity disorder; IR, immediate release.
study results, the abstract of this article reported that 65.5% 
of respondents expressed a preference for atomoxetine treat-
ment over their psychostimulant.
The remaining two studies assessing preference for a 
directly experienced treatment were double-blind choice 
procedures performed in small samples of adults (N = 10)49 
and children/adolescents (N = 5)50 who were receiving treat-
ment with MPH at the time of enrollment in the study. In both 
studies, participants received double-blind treatment with 
either placebo or MPH during each of the study ‘sampling 
sessions’, which were followed by the ‘choice sessions’ in 
which participants were asked to choose which treatment they 
would receive. Treatment options at these sessions included 
placebo, MPH, or neither treatment, with authors considering 
each participant’s choice to be an indicator of drug preference. 
In the choice procedure conducted with adult patients, MPH 
was chosen as treatment 50% of the time, placebo was chosen 
32.5% of the time, and neither treatment was chosen 17.5% of 
the time, with the difference among treatment choices being 
significant (    χ2 = 52.5, P , 0.001). In the study conducted 
with children, differences were also significant among treat-
ment choices, with participants choosing MPH 60% of the Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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time, placebo 20% of the time, and neither treatment 20% 
of the time (    χ2 = 9.6, P , 0.01).
Although heterogeneity in study designs, variation in prefer-
ence assessment methods, and differences in the ADHD treat-
ments make it difficult to draw overall conclusions from these 
five studies, some general trends did emerge. Results of the 
double-blind choice procedures suggest a preference for MPH 
over placebo among adults and children who received both 
treatments, while the crossover trial by Efron et al46 found that 
parents prefer MPH over DEX as treatment for their children. 
Results from the double-blind trial by Pelham et al48 suggest that 
less frequent dosing may be preferable among parents, while 
the study by Quintana et al47 suggests that a nonstimulant treat-
ment might be preferable for some children and adolescents. 
Overall, these studies indicate that a preference assessment may 
be a useful approach for quantifying and comparing patients’ 
or parents’ experiences with drug treatments.
Studies assessing preference  
for general treatment approaches
Table 2 presents results from the four studies assessing 
preference for a general treatment approach.51–54 All four 
studies assessed preference using a survey or questionnaire. 
In three of the studies, participants responded by indicating 
their choice among multiple options. In the study by McLeod 
et al,53 participants were asked yes/no questions regarding 
their opinions of counseling and medication treatment for 
ADHD. The authors then derived preferences based on 
the pattern of responses to these two questions. These four 
studies were conducted in samples of parents, teachers, and 
the general public. Across the four studies, the treatment 
approaches under investigation included medication-only 
regimens, nonmedication regimens (eg, counseling or behav-
ior modification approaches), and combined approaches of 
medication and nonmedication treatments.
Results of these four studies generally suggested that 
combined treatment approaches may be preferred to mono-
therapy treatment approaches for children with ADHD, but 
there is some variability in preferences. Three of the four 
studies found that a majority of respondents chose a com-
bined treatment approach (ie, medication plus counseling 
or behavior modification) over a monotherapy treatment 
approach.52–54 The respondents varied across these three stud-
ies, with samples consisting of teachers, the general public, 
and ethnically diverse parents of children with and without 
ADHD. The questionnaire included in the fourth study by 
Dos Reis et al51 included an item relating to preference, with 
authors reporting results specific to racial-ethnic comparisons 
groups. Findings suggested that nonwhite parents were less 
likely than white parents to prefer medication over counseling 
as a treatment option for children with ADHD (59% of white 
parents vs 36% of nonwhite parents, P , 0.0001).
Studies assessing preference  
for treatment attributes  
or treatment outcomes
Four studies were identified that assessed preference for 
treatment attributes or outcomes (Table 3). Unlike the studies 
presented in Table 1, participants in these studies were not 
asked to report preferences for treatments that they, or their 
children, directly experienced. Instead, respondents were 
asked to indicate a preference for attributes or outcomes relat-
ing to hypothetical treatment choices. In these four studies, 
preference was assessed by a discrete choice experiment,55 
a SG utility assessment interview,56,57 or a survey mail-out.58 
Across the three studies involving a formal preference pro-
cedure (ie, discrete choice or SG), samples included parents 
of children or adolescents with ADHD. The sample in the 
study by Stockl et al58 consisted of 365 physicians who were 
treating children and adolescents with ADHD.
Several treatment attributes and outcomes were assessed 
in these studies, including the type of treatment (eg, stimu-
lant vs nonstimulant), duration of effect, side effect profile, 
overall treatment efficacy, and impact on school and family 
functioning. Although the attributes and outcomes varied 
across these four studies, there was some consistency in 
results. Results from three studies suggested that nonstimu-
lants may be preferred over stimulants for the treatment of 
children with ADHD.56–58 In the utility studies by Matza 
et al56 and Secnik et al,57 parents expressed their prefer-
ence for a nonstimulant treatment option over a stimulant 
treatment option when both hypothetical treatments were 
otherwise equal in terms of efficacy, side effect profile, and 
other treatment attributes. The survey results reported in 
Stockl et al58 found that 38% of physicians strongly agreed 
or agreed that they would prefer prescribing a nonstimulant 
instead of a stimulant for the treatment of ADHD in children, 
provided that such options are available and Food and Drug 
Administration-approved. However, because the respondents 
did not necessarily have direct experience with nonstimulant 
medications and they were not provided with information 
on risks and benefits of stimulant treatment, these findings 
likely represent preconceived biases rather than preferences 
based on direct experience.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Table 2 Studies assessing preference for general treatment approaches
Citation Preference  
assessment method
Preference content Respondent (N) Key results
Dos Reis et al51 ASK-Me survey  
(a 47-item,  
self-administered  
questionnaire)
Parents recruited from six pediatric  
primary care clinics completed the  
ASK-Me. One item asks respondents  
to indicate level of agreement with the  
following statement: ‘[i] prefer  
medication over counseling’. Study  
results were presented by  
racial/ethnic comparison groups  
(white vs nonwhite parents)
Parents of youth  
diagnosed with  
ADHD (N = 254)
Nonwhite parents were less 
likely than white parents 
to ‘prefer medication over 
counseling’ for their children 
(59% of white parents vs 
36% of nonwhite parents, 
P , 0.0001)
Glass and wegar52 Surveys distributed  
to teachers
Surveys assessed teachers’ perceptions  
of ADHD etiology and treatment  
options. Teachers were given a choice  
of the following treatment options:  
medication, behavior modification,  
medication plus behavior modification,  
and no treatment
Teachers of  
children in  
kindergarten  
through fifth  
grade (N = 225)
94.7% of respondents 
(N = 213) chose the 
‘medication and behavior 
modification’ option as the 
most appropriate treatment 
regimen
McLeod et al53 A short battery of  
questions included in  
the 2002 General Social  
Survey, followed by  
face-to-face interviews
A subset of respondents to the 2002  
General Social Survey’s National  
Stigma Study (Children module) who  
had indicated a prior knowledge and  
awareness of ADHD and participated  
in follow-up face-to-face interviews.  
Interviews included yes/no questions  
relating to ADHD beliefs and treatment  
preferences, including ‘Should children  
be given counseling for ADHD?’ and  
‘Should children be given medication to  
treat ADHD?’ Authors used respondents’  
answers to the above yes/no questions to  
indicate beliefs and treatment preferences
General public  
survey  
respondents  
(N = 725)
Most respondents believed 
that children with ADHD 
should be given a combination 
of counseling and medication 
(65%, N = 471). 21% expressed 
a preference for counseling 
only (N = 151), 5% expressed 
a preference for medication 
only (N = 39), and 9% (N = 64) 
indicated that children with 
ADHD should receive neither 
counseling nor medication
Pham et al54 Questionnaire  
developed specifically  
for this study
Parents of children with and without  
ADHD completed a survey on ADHD- 
related beliefs and treatment. The  
survey included an item on treatment  
preference that asked parents to select  
from one of the following treatment  
options: medication only, counseling  
only, and a combined treatment  
approach. if parents did not have a  
child with ADHD, they were provided  
with a hypothetical situation in which  
their child did have ADHD
ethnically diverse  
parents of children  
(aged 5–12) with  
ADHD (N = 58)  
and without  
ADHD (N = 61)
53.8% of parents preferred a 
combined treatment approach 
for their child, 24.4% 
preferred counseling only, 
16.8% preferred medication 
only, and 5.0% responded 
‘none of the above’ to the 
provided treatment options
Abbreviations: ASK-ME, attitudes, satisfaction, knowledge, and medication experiences survey; ADHD, attention-deficit/hyperactivity disorder.
Two additional trends that emerged across these stud-
ies were a preference for treatments with no known abuse 
potential and a preference for treatments with better (ie, more 
  tolerable) side effect profiles. Physicians completing the survey 
administered by Stockl et al58 and parents participating in the 
discrete choice experiment described by Muhlbacher et al55 
indicated their preference for treatments with no known abuse 
potential over treatments with evidence of abuse   potential. 
Parents participating in the utility study by Matza et al56 and 
the discrete choice experiment by Muhlbacher et al55 indicated 
that the side effect profile of a hypothetical ADHD medication 
was important in the selection of and preference for an ADHD 
treatment. Specific side effects that influenced preference in 
these studies included incidence of nausea, changes in weight 
and appetite, and whether the medication made the children 
feel drowsy or more ‘wired’.
Apart from the trends that emerged in the treatment 
attributes discussed above, the discrete choice experiment Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Van Brunt et al
by Muhlbacher et al55 assessed additional treatment charac-
teristics that were not investigated in the other studies. This 
study found that treatments with a longer duration of action, 
greater potential for improvements in emotional state, and 
enhanced ability to enable social contacts would have the 
most influence in the parents’ selection of treatment for their 
children with ADHD. These findings suggest that real-world 
outcomes, in addition to treatment efficacy, contribute to 
preferences for their children’s treatment.
Studies not assessing a  
treatment-related aspect of ADHD
Finally, two additional studies were located that assessed 
preference for an aspect of ADHD that was not related to 
treatment. One study recruited a sample of 99 parents of 
children with ADHD to complete a survey assessing the 
importance placed on types of ADHD information and the 
preferred modes of receiving this information.59 Parents were 
asked to preferentially rank the following ways of receiv-
ing information about their child’s ADHD: verbal, written, 
DVD/video, seminars, parenting class, audio, Internet, video, 
and CD-ROM. Authors found the most preferred mode 
of information delivery to be verbal information received 
directly from a professional, with written information being 
the second most preferred option.
Another study involved semistructured follow-up inter-
views with 19 teachers of elementary school students with 
ADHD who had participated in a 2-month clinical trial of 
an unspecified ADHD treatment.60 The teachers were asked 
to compare the Web-based ADHD symptom rating scale 
that they completed during the trial (the T-SKAMP) to their 
previous experience with paper-and-pencil ADHD scales. 
Results of the interviews found teachers to generally prefer 
the Web-based scale, with 89.5% of teachers indicating that 
it was easier to complete than the paper-based scale.
Discussion
ADHD may be treated with a range of potentially effective 
pharmacological and behavioral treatment options. Because 
there is not a dominant treatment known to be the first choice 
for all patients, ADHD is a condition for which individual 
preferences can play an important role when determining a 
treatment approach for individual patients. In studies iden-
tified for the current review, a wide range of measurable 
treatment preferences were reported by patients with ADHD, 
clinicians, parents, teachers, and survey respondents from 
the general population. However, this literature search found 
only 15 studies using a choice-based preference assessment 
related to ADHD. Given the potential role of preferences in 
clinical decision-making, more research is needed to better 
understand the preferences of patients with ADHD and other 
individuals who are directly affected by the disorder, such 
as parents and teachers.
Five studies were identified that assessed preference 
between two treatment options directly experienced by 
the respondent or the respondent’s child, and all five stud-
ies yielded clear preferences (Table 1). Parents expressed 
preferences among stimulant treatment options,46,48 children 
expressed preferences for a nonstimulant over a stimulant,47 
and small samples of children and adults expressed prefer-
ences for MPH over placebo.49,50 One limitation of the current 
review is that clinical trials assessing preferences among 
ADHD treatment options would not have been located if they 
did not mention ‘preference’ or a related term in the published 
abstract. Therefore, it is possible that the current literature 
search failed to identify some published clinical trials that 
included a preference measure, but did not mention it in the 
abstract. Despite this limitation, results of the five identified 
studies suggest that preference data can complement clinical 
symptom measures by providing insight into the experiences 
of individuals directly affected by treatments. Based on these 
five studies, assessment of preference can be recommended 
for inclusion as an outcome measure in future clinical trials 
with study designs that allow patients to experience more 
than one treatment option. These preference assessments are 
more likely to yield useful results if the assessment tools are 
carefully developed and validated in the target population.
Additional studies assessed preferences for treatment 
approaches and attributes among respondents who did not 
necessarily have recent direct experience with the treatment 
options. Although these preferences were not assessed in the 
context of a controlled clinical trial, results may still provide 
useful information for clinical decision-makers. For example, 
parents, teachers, and general public survey respondents 
expressed preferences for combined treatment approaches 
involving both medication and nonpharmacological treatment 
such as counseling and behavioral modification.52–54 Three 
additional studies revealed preferences for nonstimulant 
medications over stimulants among clinicians and parents.56–58 
Another study identified several therapy characteristics 
that may influence parents’ treatment preferences, such as 
addictive potential, improvement in concentration, effects 
on social functioning, emotional impact, duration of effect, 
dosage, and side effects.55 Finally, one study found that par-
ent preferences for medication and counseling may vary as a 
function of racial/ethnic background.51 Taken together, these Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
41
Preferences related to ADHD and its treatment
studies provide insight into factors that may influence patient, 
parent, and clinician preferences for ADHD treatment, such as 
treatment characteristics, effectiveness for specific symptoms, 
side effects, and respondent demographics. The variety of 
available treatment approaches and factors that can influence 
treatment preference underscores the importance of custom-
izing treatment decisions based on the needs and preferences 
of each individual patient, as no single treatment approach will 
be suitable for all patients. Additional research on treatment 
and patient characteristics that influence preference could 
provide useful guidance for clinicians involved in choosing 
among treatment options for individual patients.
One significant gap identified in the current literature 
review is the minimal available research on treatment pref-
erences of adults with ADHD. Although ADHD is often 
believed to be a disorder of childhood, symptoms such as 
inattention and impulsivity often persist into adulthood.14–16,61 
Furthermore, pharmacological and psychosocial treatments 
are being developed, tested, and implemented in adults with 
ADHD.62–68 However, the current literature search identi-
fied only one study examining preferences of adults with 
ADHD, and this study was conducted with a small sample.49 
Since there is a wide range of potentially effective treatment 
approaches for adult ADHD, research is needed to understand 
the treatment preferences of this population.
Another limitation of this literature is that most studies 
did not use carefully developed and validated instruments 
to assess preference. Some studies used invalidated global 
items,46 while others did not clearly describe the method of 
preference assessment.47,48 Since the introduction of the Food 
and Drug Administration guidance on patient-reported out-
comes, there has been a growing awareness of the importance 
of using carefully developed instruments that are validated 
for use in the target population.69 We recommend that future 
studies of ADHD treatment incorporate more rigorously 
developed preference assessment methods, which can be 
clearly described in published articles.
Despite limitations of the currently available literature, 
findings of this review suggest that preference assessment 
could provide a useful indication of patients’ experiences with 
various treatment options. Across the 15 studies in this review, 
patients, parents, clinicians, and teachers were able to provide 
quantifiable preferences among multiple treatment options, 
and research has begun to identify treatment- and respondent-
related factors that influence these preferences. As research on 
preferences related to ADHD grows, findings may be applied in 
clinical decision-making. Although current ADHD treatment 
guidelines acknowledge that parents and families may play 
a role in choosing a treatment,70,71 no guidance based on 
preference research is provided. As preference data   accumulate 
in ADHD studies, findings could be incorporated into the 
decision-making process as described in treatment guidelines. 
Furthermore, such guidelines could encourage clinicians to 
include patients and families in the decision-making process. 
Additional research findings may help clinicians know how to 
initiate and facilitate these discussions. Finally, decision aids, 
such as booklets or Web sites, may be developed to provide 
information that will assist patients and parents as they contrib-
ute to their own treatment decisions.72 Such decision aids have 
helped patients with other conditions develop their treatment 
preferences based on knowledge and information.73 It is likely 
that patients and families affected by ADHD may experience 
similar benefits. ADHD may be particularly appropriate for 
consideration of patient preferences in the use of decision aids 
because it is a condition with a range of potentially effective 
treatment options. ADHD can be addressed with behavioral 
treatment, stimulant medication, nonstimulant medication, and 
a combination of behavioral and pharmacological treatments. 
Treatment approaches that help educate patients and parents 
while considering their preferences may be more effective than 
treatment decisions based on efficacy alone.
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